88
6
3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TP1889 | MCL0020 | MCL 0020 | Melanocortin Receptor |
MCL0020 is a potent and selective melanocortin MC4 receptor antagonist (IC50 values are 11.63, 1115 and > 10 000 nM at MC4, MC3 and MC1 receptors respectively). Significantly reverses stress-induced anorexia but has no e... | |||
T12041 | MIM1 | Inhibitor of Mcl-1 | BCL |
MIM1 (Inhibitor of Mcl-1) is an myeloid cell factor 1 (Mcl-1) inhibitor. | |||
T11967 | Mcl-1 antagonist 1 | Others | |
Mcl-1 antagonist 1 is a Mcl-1 protein antagonist. | |||
T40230 | Mcl-1 inhibitor 6 | ||
Mcl-1 inhibitor 6 is a potent, orally active chemical compound that selectively inhibits the myeloid cell leukemia 1 (Mcl-1) protein, with a high affinity (K d = 0.23 nM) and binding activity (K i = 0.02 μM). This compou... | |||
T11972 | Mcl-1 inhibitor 3 | BCL | |
Mcl-1 inhibitor 3 shows good pharmacokinetic properties and excellent in vivo efficacy without toxicity.Mcl-1 inhibitor 3 is a highly potent and orally activate macrocyclic Mcl-1 inhibitor (Ki= 0.061 nM; IC50=19 nM in an... | |||
T11971 | MCL-1/BCL-2-IN-4 | Others | |
MCL-1/BCL-2-IN-4 is a selective and potent Mcl-1 and Bcl-2 dual inhibitor. | |||
T11968 | MCL-1/BCL-2-IN-1 | BCL | |
MCL-1/BCL-2-IN-2 (Compound Nap-1) is a potent and selective dual inhibitor of Mcl-1 and Bcl-2 with IC 50 s of 4.45 and 3.18 μM, respectively [1]. | |||
T11969 | MCL-1/BCL-2-IN-2 | Others | |
MCL-1/BCL-2-IN-2 is a potent and selective Bcl-2 and Mcl-1 dual inhibitor. | |||
T11970 | MCL-1/BCL-2-IN-3 | Others | |
MCL-1/BCL-2-IN-3 is a selective and potent Mcl-1 and Bcl-2 dual inhibitor with IC50s of 5.95 and 4.78 μM, respectiely. | |||
T27997 | MDK-3345 | MDK 3345,Mcl-1 Inhibitor11,Mcl-1 Inhibitor 11,Mcl-1 Inhibitor-11 | |
MDK-3345 is a reversible covalent inhibitor for Mcl-1. | |||
T27986 | MCL0129 | MCL-0129,MCL 0129 | |
MCL0129, a selective and non-peptidergic melanocortin 4 (MC4) receptor antagonist, is a potential treatment for cachexia. | |||
T72610 | Mcl-1 inhibitor 9 | ||
Mcl-1 Inhibitor 9 (Example 2) is a potent inhibitor of myeloid cell leukemia 1 (Mcl-1), demonstrating anti-tumor activity with an IC50 value of 0.21889 nM. | |||
T79036 | Mcl-1 inhibitor 13 | ||
Mcl-1 Inhibitor 13 (Example 9), with a Ki of 8.2 nM, serves as an MCL-1 inhibitor suitable for cancer research [1]. | |||
T27996 | MDK-3298 | Mcl-1 Inhibitor-5,Mcl-1 Inhibitor 5,MDK3298,Mcl-1 Inhibitor5 | |
MDK-3298 is a reversible covalent inhibitor of Mcl-1, a target of protein-protein interaction (PPI). | |||
T75143 | Mcl-1 inhibitor 12 | ||
Mcl-1 Inhibitor 12 (Example 10), with a K i of 0.22 nM, functions as an MCL-1 inhibitor. It is utilized in cancer research [1]. | |||
T79215 | Mcl-1 inhibitor 14 | ||
Compound (Ra)-10, also known as Mcl-1 inhibitor 14, is a potent inhibitor of myeloid cell leukemia-1 (MCL-1), exhibiting a K_i of 0.018 nM, and holds potential for use in anticancer research [1]. | |||
T79216 | Mcl-1 inhibitor 15 | ||
Mcl-1 Inhibitor 15 (Compound (Ra)-15), with a K i of 0.02 nM, is utilized in cancer research [1]. | |||
T79242 | Mcl-1 inhibitor 16 | ||
Mcl-1 Inhibitor 16 (Compound 9), a platinum-based mitochondrial-targeting agent, inhibits Mcl-1 and induces Bax/Bak-dependent apoptosis in cancer cells. This compound exhibits antitumor activity and may be utilized as a ... | |||
T62443 | Bcl-2/Mcl-1-IN-2 | ||
Bcl-2/Mcl-1-IN-2 is a Bcl-2 (Ki: 4.70 μM) and Mcl-1 (Ki: 0.88 μM) inhibitor.Bcl-2/Mcl-1-IN-2 can be used in cancer research. | |||
T62249 | Bcl-2/Mcl-1-IN-1 | ||
Bcl-2/Mcl-1-IN-1 is an inhibitor of Bcl-2 (Ki: 4.53 μM) and Mcl-1 (Ki: 1.19 μM).Bcl-2/Mcl-1-IN-1 can be used in cancer research. | |||
T62941 | Bcl-2/Mcl-1-IN-3 | ||
Bcl-2/Mcl-1-IN-3 is a Bcl-2/Mcl-1 inhibitor that acts on Mcl-1 (Ki: 0.14 μM) and Bcl-2 (Ki: 0.23 μM) and can be used in cancer research. | |||
T10096L | Voruciclib | CDK | |
Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM). Voruciclib represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma. Voruciclib effectively blocks CDK9, the ... | |||
T18487 | NH2-C6-NH-Boc | Others , PROTAC Linker | |
NH2-C6-NH-Boc is a PROTAC linker. NH2-C6-NH-Boc can be used in the synthesis the Mcl-1 inhibitor based on PROTAC. | |||
T11976 | Mcl1-IN-4 | Others | |
Mcl1-IN-4 is an inhibitor of Mcl1 ( IC50:0.2 μM). | |||
T68398 | MI-223 | ||
MI-223 is an inhibitor of Mcl-1-stimulated homologous recombination (HR) DNA repair, which leads to sensitization of cancer cells to hydroxyurea- or olaparib-induced DNA replication stress. | |||
T16156 | MT 63-78 | Apoptosis , AMPK , mTOR | |
MT 63-78 is a specific and effective direct AMPK activator (EC50: 25 μM). MT 63-78 blocks prostate cancer growth by inhibiting the lipogenesis and mTORC1 pathways. MT 63-78 has antitumor effects. MT 63–78 also causes cel... | |||
T16030 | Mcl1-IN-8 | Others | |
Mcl1-IN-8 is an Mcl-1-PUMA interface inhibitor (Ki: 0.3 μM). In cancer cells, Mcl1-IN-8 shows dual activity on reducing PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis. | |||
T11977 | Mcl1-IN-9 | BCL | |
Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC50 of 446 nM in reengineered BCR-ABL+ B-ALL cells and a Ki of 0.03 nM. | |||
T11974 | Mcl1-IN-12 | BCL | |
Mcl1-IN-12 has anti-tumor activity.It is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.29 and 3.1 μM, respectively. | |||
T11973 | Mcl1-IN-11 | BCL | |
Mcl1-IN-11 (Compound G) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with Kis of 0.06 and 4.2 μM, respectively. | |||
T16029 | Mcl1-IN-3 | Others | |
Mcl1-IN-3 is an Mcl1 inhibitor. It has an IC50 and Ki of 0.67 and 0.13 μM, respectively. | |||
T16027 | Mcl1-IN-1 | Others | |
Mcl1-IN-1 is a myeloid cell factor 1 inhibitor (IC50=2.4 µM). | |||
T24436 | Mcl1-IN-26 | ||
Mcl1-IN-26 is an effective and selective myeloid cell leukemia 1 inhibitor. | |||
T11975 | PROTAC Mcl1 degrader-1 | BCL | |
PROTAC Mcl1 degrader-1 induces the ubiquitination and proteasomal degradation of Mcl-1 by introducing the E3 ligase cereblon (CRBN)-binding ligand pomalidomide to Mcl-1 inhibitor S1-6 with μM-range affinity. PROTAC Mcl1 ... | |||
T2558 | Cladribine | 2-chlorodeoxyadenosine,2-Chloro-2′-deoxyadenosine,CldAdo,2CdA | Apoptosis , Adenosine deaminase |
Cladribine (2CdA), an adenosine deaminase inhibitor, is utilized in the treatment of lymphoproliferative diseases. | |||
T16028 | IMB-XH1 | Mcl1-IN-2 | BCL , Antibacterial |
IMB-XH1 (Mcl1-IN-2) is a myeloid cell factor 1 (Mcl-1) inhibitor. | |||
T24812 | SOMCL-863 | ||
SOMCL-863 is a selective and orally bioavailable c-Met inhibitor. It shows antitumor activity both in vitro and in vivo. | |||
T19024 | MCLA hydrochloride | Others | |
MCLA hydrochloride, a chemiluminescent compound, can be used to quantify aqueous concentrations of superoxide. | |||
T13657 | DMCL1-2 | Others | |
dMCL1-2 is a potent and selective myeloid leukemia 1 (MCL1) degrading agent based on PROTAC, which binds to MCL1 with a KD of 30 nM. dmcl-2 activates the apoptosis mechanism by degrading MCL1. | |||
T2632 | A-1210477 | Apoptosis , BCL | |
A-1210477 is an effective and specific MCL-1 and Bcl-2 inhibitor (Ki/IC50: 0.454/26.2 nM). | |||
T5108 | ML311 | BCL | |
ML311 is a selective inhibitor of the Mcl-1/Bim interaction. | |||
T6034 | UMI-77 | UMI77,UMI 77 | BCL |
UMI-77, a specific Mcl-1 inhibitor (Ki: 490 nM), has selectivity over other members of Bcl-2 family. | |||
T17247 | VU0661013 | VU661013 | BCL |
VU0661013 is an effective and selective inhibitor of MCL-1. | |||
T6281 | TW-37 | TW 37 | BCL |
TW-37 is an nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 (Ki: 0.29/1.11/0.26 μM). | |||
T6396 | (R)-(-)-Gossypol acetic acid | (-)-Gossypol acetic acid,AT-101 (acetic acid),(R)-Gossypol acetic acid,AT101,AT101 acetate | BCL , Autophagy |
(R)-(-)-Gossypol acetic acid (AT101 acetate) , the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM; does not inhibit BIR3 domain and BID. Phase 2. | |||
T6650 | Sabutoclax | BI-97C1 | BCL |
Sabutoclax (BI-97C1)(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively. | |||
T11944 | Maritoclax | Marinopyrrole A | BCL |
Maritoclax (Marinopyrrole A) (Marinopyrrole A) is a novel and specific Mcl-1 inhibitor, shows >8 fold selectivity than BCL-xl (IC50 > 80 μM),with an IC50 value of 10.1 μM. | |||
T14665L | Motixafortide TFA(664334-36-5,Free) | TF 14016 TFA,BKT140 TFA,BL-8040 TFA,T140 TFA | CXCR |
Motixafortide TFA(664334-36-5,Free) (BKT140 TFA) is an antagonist of CXCR4 with IC50 of ~1 nM. It induces the apoptosis of AML blasts by down-regulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression... | |||
T13639 | Deferasirox (Fe3+ chelate) | Apoptosis | |
Deferasirox (Fe3+ chelate) is an orally available iron chelator with potential anticancer activity, inhibits the anti-apoptotic activity of MCL-1, and can be used to study iron overload. | |||
T5346 | S63845 | BCL | |
S63845 is a selective MCL-1 inhibitor(Kd: 0.19 nM) |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T6185 | Gambogic Acid | Beta-Guttiferrin,Guttatic Acid,Guttic Acid | BCL , Autophagy |
Gambogic Acid (Guttic Acid) ( EC50=0.78-1.64 uM) activates caspases. Gambogic Acid competitively suppresses Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 and Mcl-1. The IC50s of Gambogic Acid for Bcl-XL, Bcl-2, Bcl-W, Bcl-B, Bfl-1 ... | |||
T5688 | Micheliolide | NOS , NF-κB , COX | |
Micheliolide(MCL) is a sesquiterpene lactone which inhibits various inflammatory response. | |||
T5668 | Triacetylresveratrol | Acetyl-trans-resveratrol | BCL , NF-κB , STAT |
Triacetylresveratrol (Acetyl-trans-resveratrol) has anti-cancer activity,it inhibits the phosphorylation of STAT3 and NFκB, down-regulates Mcl-1, and up-regulates Bim and Puma in pancreatic cancer cells. | |||
T2730 | Gossypol (acetic acid) | (±)-Gossypol-acetic acid,Pogosin,AT101,Gossypol acetic acid | BCL |
Gossypol acetic acid (AT101), a polyphenolic compound isolated from cottonseeds, binds with Bcl-2, Bcl-xL, Mcl-1, and does not inhibit BIR3 domain and BID. | |||
T30969 | Clitocine | Apoptosis , BCL | |
Clitocine, an adenosine analogue derived from mushrooms, is a potent transcriptional readout agent, an inhibitor of nonsense mutations, and has anticancer activity, inducing the production of p53 protein in cells carryin... | |||
T3824 | Jaceosidin | Apoptosis , BCL , COX , UGT | |
Jaceosidin has anti-oxidative activity. Jaceosidin has anti-inflammatory activity, also a microglial inhibitor with anti-neuroinflammation activity. aceosidin has anticancer activity, modulates the ERK/ATM/Chk1/2 pathway... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02003 | FH/Fumarate Hydratase Protein, Human, Recombinant (His) | Human | E. coli |
Fumarate Hydratase (FH) is an enzymatic component of the tricarboxylic acid (TCA) cycle, or Krebs cycle, and catalyzes the formation of L-malate from fumarate. It exists in both a cytosolic form and an N-terminal extende... | |||
TMPY-01643 | CLEC4D Protein, Human, Recombinant (His) | Human | HEK293 Cells |
CLEC4D Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 21.2 kDa and the accession number is Q8WXI8. | |||
TMPY-02293 | CD23 Protein, Human, Recombinant (His) | Human | HEK293 Cells |
CD23 Protein, Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag. The predicted molecular weight is 33.2 kDa and the accession number is P06734-1. |